A Phase 3 interventional study of adalimumab and Calcipotriol/Betamethasone Ointment in Chronic Plaque Psoriasis, sponsored by Abbott. Completed at 131 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-04-13.
Sponsored by Abbott · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies testing calcipotriene in Psoriasis — 2 open to participants now, 2 under way, none of them phase 3. calcipotriene · Psoriasis.
Among the 47 studies testing calcipotriene in Psoriasis, this one is the 9th largest by enrollment, is one of 2 that started in 2007, is one of 17 in phase 3, and was the 11th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →2 of the 47 studies testing calcipotriene in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:
Xijing Hospital · Sites in China
Ages 18–65
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
calcipotriene: first FDA approval 1993 (DOVONEX). What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 12 · Phase 3 19 · Phase 4 12
First in 2004; this study’s year is marked. 2 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 730 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 200 across the 47 interventional studies. Of the 41 that completed or were terminated, 21 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 47 have an industry lead sponsor. The 10 most frequent:
Abbott is the lead sponsor of 361 studies on the registry; 1 is open to participants now.
16 studies in Psoriasis by Abbott: none open now, none under way, none of them phase 3. Of 15 finished, 8 (53%) have results posted.
Among the 16 studies in Psoriasis by Abbott, this one is the 3rd largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2007, is one of 6 in phase 3, and was the 7th registered.
Abbott’s Psoriasis studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 47 studies testing calcipotriene in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Abbott’s 16 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to assess the efficacy and safety of adalimumab in combination with topical psoriasis treatment, calcipotriol/betamethasone, vs. adalimumab in combination with matching vehicle in subjects with moderate to severe chronic plaque psoriasis.
Additional information regarding sponsors: Abbott GmbH \& Co. KG is sponsor for EU member states. Abbott US is sponsor for non-EU member states.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
adalimumab + placebo (vehicle ointment)
Biological: adalimumab · Drug: placebo (vehicle ointment)
adalimumab + calcipotriol/betamethasone ointment
Biological: adalimumab · Drug: Calcipotriol/Betamethasone Ointment
subcutaneous injection using prefilled pen/syringe, solution containing 40 mg in 0.8 milliliters; 2 injections given at Baseline (Day 1) then once every other week from Weeks 1 though 15
Also known as: ABT-D2E7, Humira
Drug pages: Calcipotriene · Betamethasone
Topical ointment (calcipotriol 50 mcg/g and betamethasone 500 mcg/g) to be applied once daily to affected psoriasis skin on trunk and extremities for first 4 weeks and as needed from Week 5 through Week 16
Also known as: Daivobet
Topical vehicle ointment (matching active calcipotriol/betamethasone ointment) to be applied once daily to affected psoriasis skin on trunk and extremities for first 4 weeks and as needed from Week 5 through Week 16
Percentage of Participants Who Achieve a PASI75 Response at Week 16 Compared With Baseline (Week 0)
PASI75 is defined as at least a 75% reduction in PASI (Psoriasis Area and Severity Index) score compared with the Baseline PASI score. PASI scores range from 0.0 (best) to 72.0 (worst), with the highest score representing complete erythroderma of the severest degree. The percent decrease in score is calculated as (Week 0 PASI score minus Week 16 PASI score) divided by Week 0 PASI score. Positive percent decreases indicate improvement, with best improvement being 100%. The outcome measure is the percentage of participants who had at least a 75% PASI score decrease.
Time frame: Week 0 and Week 16
Percentage of Participants With a PASI50 Response at Week 16 Compared With Baseline (Week 0)
PASI50 is defined as at least a 50% reduction in PASI (Psoriasis Area and Severity Index) score compared with the Baseline PASI score. PASI scores range from 0.0 (best) to 72.0 (worst), with the highest score representing complete erythroderma of the severest degree. The percent decrease in score is calculated as (Week 0 PASI score minus Week 16 PASI score) divided by Week 0 PASI score. Positive percent decreases indicate improvement, with best improvement 100%. The outcome measure is the percentage of participants who had at least a 50% PASI score decrease.
Time frame: Week 0 and Week 16
Percentage of Participants With a PASI90 Response at Week 16 Compared With Baseline (Week 0)
PASI90 is defined as at least a 90% reduction in PASI (Psoriasis Area and Severity Index) score compared with the Baseline PASI score. PASI scores range from 0.0 (best) to 72.0 (worst), with the highest score representing complete erythroderma of the severest degree. The percent decrease in score is calculated as (Week 0 PASI score minus Week 16 PASI score) divided by Week 0 PASI score. Positive percent decreases indicate improvement, with best improvement 100%. The outcome measure is the percentage of participants who had at least a 90% PASI score decrease.
Time frame: Week 0 and Week 16
Percentage of Participants With a PASI100 Response at Week 16 Compared With Baseline (Week 0)
PASI100 is defined as at least a 100% reduction in PASI (Psoriasis Area and Severity Index) score compared with the Baseline PASI score. PASI scores range from 0.0 (best) to 72.0 (worst) with the highest score representing complete erythroderma of the severest degree. The percent decrease in score is calculated as (Week 0 PASI score minus Week 16 PASI score) divided by Week 0 PASI score. Positive percent decreases indicate improvement, with best improvement 100%. The outcome measure is the percentage of participants who had at least a 100% PASI score decrease.
Time frame: Week 0 and Week 16
Percentage of Participants Achieving a Physician's Global Assessment (PGA) of Clear or Minimal at Week 2
PGA is a physician's assessment of severity of disease (grading lesion severity). PGA scores range from 0 (best) to 6 (worst): on the 6-point scale, a score of 0 = Clear and a score of 6 = Very Severe for the lesion severity. PGA Clear (0) is no plaque elevation over normal skin and no scale with or without erythema. Minimal (1) is possible plaque elevation but difficult to ascertain a slight elevation above normal skin. Percentage of participants: 0% to 100% (best).
Time frame: Week 2
Percentage of Participants Achieving a Physician's Global Assessment (PGA) of Clear or Minimal at Week 4
PGA is a physician's assessment of severity of disease (grading lesion severity). PGA scores range from 0 (best) to 6 (worst): on the 6-point scale, a score of 0 = Clear and a score of 6 = Very Severe for the lesion severity. PGA Clear (0) is no plaque elevation over normal skin and no scale with or without erythema. Minimal (1) is possible plaque elevation but difficult to ascertain a slight elevation above normal skin. Percentage of participants: 0% to 100% (best).
Time frame: Week 4
Percentage of Participants Achieving a Physician's Global Assessment (PGA) of Clear or Minimal at Week 8
PGA is a physician's assessment of severity of disease (grading lesion severity). PGA scores range from 0 (best) to 6 (worst): on the 6-point scale, a score of 0 = Clear and a score of 6 = Very Severe for the lesion severity. PGA Clear (0) is no plaque elevation over normal skin and no scale with or without erythema. Minimal (1) is possible plaque elevation but difficult to ascertain a slight elevation above normal skin. Percentage of participants: 0% to 100% (best).
Time frame: Week 8
Percentage of Participants Achieving a Physician's Global Assessment (PGA) of Clear or Minimal at Week 12
PGA is a physician's assessment of severity of disease (grading lesion severity). PGA scores range from 0 (best) to 6 (worst): on the 6-point scale, a score of 0 = Clear and a score of 6 = Very Severe for the lesion severity. PGA Clear (0) is no plaque elevation over normal skin and no scale with or without erythema. Minimal (1) is possible plaque elevation but difficult to ascertain a slight elevation above normal skin. Percentage of participants: 0% to 100% (best).
Time frame: Week 12
Percentage of Participants Achieving a Physicians Global Assessment (PGA) Response of Clear or Minimal at Week 16
PGA is a physician's assessment of severity of disease (grading lesion severity). PGA scores range from 0 (best) to 6 (worst): on the 6-point scale, a score of 0 = Clear and a score of 6 = Very Severe for the lesion severity. PGA Clear (0) is no plaque elevation over normal skin and no scale with or without erythema. Minimal (1) is possible plaque elevation but difficult to ascertain a slight elevation above normal skin. Percentage of participants: 0% to 100% (best).
Time frame: Week 16
Percent Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 16 Compared With Baseline (Week 0)
DLQI is a participant-reported outcome consisting of a set of 10 questions regarding the degree to which (i.e., how much) the subject's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much, a lot, a little, or not at all. Total score range: 0 (best) to 30 (worst). Negative change and percent change from Baseline indicate improvement, with best improvement -100%.
Time frame: Week 0 and Week 16
Percent Change in the Dermatology Life Quality Index (DLQI) Total Score at Week 2 Compared With Baseline (Week 0)
DLQI is a participant-reported outcome consisting of a set of 10 questions regarding the degree to which (i.e., how much) the subject's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much, a lot, a little, or not at all. Total score range: 0 (best) to 30 (worst). Negative change and percent change from Baseline indicate improvement, with best improvement -100%.
Time frame: Week 0 and Week 2
Percent Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 4 Compared With Baseline (Week 0)
DLQI is a participant-reported outcome consisting of a set of 10 questions regarding the degree to which (i.e., how much) the subject's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much, a lot, a little, or not at all. Total score range: 0 (best) to 30 (worst). Negative change and percent change from Baseline indicate improvement, with best improvement -100%.
Time frame: Week 0 and Week 4
Percent Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 8 Compared With Baseline (Week 0)
DLQI is a participant-reported outcome consisting of a set of 10 questions regarding the degree to which (i.e., how much) the subject's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much, a lot, a little, or not at all. Total score range: 0 (best) to 30 (worst). Negative change and percent change from Baseline indicate improvement, with best improvement -100%.
Time frame: Week 0 and Week 8
Percent Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 12 Compared With Baseline (Week 0)
DLQI is a participant-reported outcome consisting of a set of 10 questions regarding the degree to which (i.e., how much) the subject's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much, a lot, a little, or not at all. Total score range: 0 (best) to 30 (worst). Negative change and percent change from Baseline indicate improvement, with best improvement -100%.
Time frame: Week 0 and Week 12
Percent Change in Short Form 36 Health Survey (SF-36) Physical Component Score (PCS) at Week 16 Compared With Baseline (Week 0)
Short Form 36 Health Survey (SF-36) Physical Component Score (PCS) is a participant-reported outcome that employs a questionnaire that asks for the participant's views about their health. Percent change at Week 16 is calculated as (Week 16 SF-36 PCS minus Week 0 SF-36 PCS) divided by Week 0 SF-36 PCS. Positive percent change in score indicates improvement, with best improvement 100%.
Time frame: Week 0 and Week 16
Percent Change in Short Form 36 Health Survey (SF-36) Physical Component Score (PCS) at Week 8 Compared With Baseline (Week 0)
Short Form 36 Health Survey (SF-36) Physical Component Score (PCS) is a participant-reported outcome that employs a questionnaire that asks for the participant's views about their health. Percent change at Week 8 is calculated as (Week 8 SF-36 PCS minus Week 0 SF-36 PCS) divided by Week 0 SF-36 PCS. Positive percent change in score indicates improvement, with best improvement 100%.
Time frame: Week 0 and Week 8
Percent Change in Psoriasis Scalp Severity Index (PSSI) From Baseline to Week 16.
PSSI is a physician assessment of clinical symptoms of scalp psoriasis. Computed as the sum of scores for erythema, induration, and desquamation (1 = absent; 4 = severest possible) multiplied by involved area (0 = 0%; 6 = 90-100%). Total score range: 0 (best) to 72 (worst). Negative change and percent change from Baseline indicate improvement.
Time frame: Week 0 and Week 16
Percent Change in Nail Psoriasis Severity Index (NAPSI) at Week 16.
NAPSI is a sum of 2 scores that grade nail matrix psoriasis (based on presence/absence of pitting, leukonychia, red spots in the lunula, and nail plate crumbling) and nail bed psoriasis (based on presence/absence of onycholysis splinter hemorrhages, oil drop \[salmon patch\] discoloration, and nail bed hyperkeratosis). Each fingernail is given a single score based on presence of psoriasis in quadrant of nail: 0 (none) to 4 (present in 4/4 nail quadrants). Score range: 0 (best) to 80 (worst). Negative change and percent change from Baseline indicate improvement.
Time frame: Week 0 and Week 16
| Milestone | Adalimumab + Placebo | Adalimumab + Calcipotriol/Betamethasone |
|---|---|---|
| Started | 364 | 366 |
| Completed | 338 | 338 |
| Not completed | 26 | 28 |
| Withdrew: Adverse event | 6 | 18 |
| Withdrew: Lack of efficacy | 5 | 3 |
| Withdrew: Lost to follow-up | 4 | 3 |
| Withdrew: Protocol violation | 5 | 2 |
| Withdrew: History of carcinoma | 1 | 0 |
| Withdrew: Withdrawal by subject | 3 | 0 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Pregnancy | 1 | 0 |
| Withdrew: Excluded by company | 0 | 1 |
| Withdrew: Ppd test taken twice | 0 | 1 |
PASI75 is defined as at least a 75% reduction in PASI (Psoriasis Area and Severity Index) score compared with the Baseline PASI score. PASI scores range from 0.0 (best) to 72.0 (worst), with the highest score representing complete erythroderma of the severest degree. The percent decrease in score is calculated as (Week 0 PASI score minus Week 16 PASI score) divided by Week 0 PASI score. Positive percent decreases indicate improvement, with best improvement being 100%. The outcome measure is the percentage of participants who had at least a 75% PASI score decrease.
| percentage of participants | Adalimumab + Placebo | Adalimumab + Calcipotriol/Betamethasone |
|---|---|---|
| Percentage of Participants Who Achieve a PASI75 Response at Week 16 Compared With Baseline (Week 0) | 70.9 | 64.8 |
PASI50 is defined as at least a 50% reduction in PASI (Psoriasis Area and Severity Index) score compared with the Baseline PASI score. PASI scores range from 0.0 (best) to 72.0 (worst), with the highest score representing complete erythroderma of the severest degree. The percent decrease in score is calculated as (Week 0 PASI score minus Week 16 PASI score) divided by Week 0 PASI score. Positive percent decreases indicate improvement, with best improvement 100%. The outcome measure is the percentage of participants who had at least a 50% PASI score decrease.
| percentage of participants | Adalimumab + Placebo | Adalimumab + Calcipotriol/Betamethasone |
|---|---|---|
| Percentage of Participants With a PASI50 Response at Week 16 Compared With Baseline (Week 0) | 82.7 | 80.9 |
PASI90 is defined as at least a 90% reduction in PASI (Psoriasis Area and Severity Index) score compared with the Baseline PASI score. PASI scores range from 0.0 (best) to 72.0 (worst), with the highest score representing complete erythroderma of the severest degree. The percent decrease in score is calculated as (Week 0 PASI score minus Week 16 PASI score) divided by Week 0 PASI score. Positive percent decreases indicate improvement, with best improvement 100%. The outcome measure is the percentage of participants who had at least a 90% PASI score decrease.
| percentage of participants | Adalimumab + Placebo | Adalimumab + Calcipotriol/Betamethasone |
|---|---|---|
| Percentage of Participants With a PASI90 Response at Week 16 Compared With Baseline (Week 0) | 50.3 | 38.8 |
PASI100 is defined as at least a 100% reduction in PASI (Psoriasis Area and Severity Index) score compared with the Baseline PASI score. PASI scores range from 0.0 (best) to 72.0 (worst) with the highest score representing complete erythroderma of the severest degree. The percent decrease in score is calculated as (Week 0 PASI score minus Week 16 PASI score) divided by Week 0 PASI score. Positive percent decreases indicate improvement, with best improvement 100%. The outcome measure is the percentage of participants who had at least a 100% PASI score decrease.
| percentage of participants | Adalimumab + Placebo | Adalimumab + Calcipotriol/Betamethasone |
|---|---|---|
| Percentage of Participants With a PASI100 Response at Week 16 Compared With Baseline (Week 0) | 24.2 | 15.3 |
PGA is a physician's assessment of severity of disease (grading lesion severity). PGA scores range from 0 (best) to 6 (worst): on the 6-point scale, a score of 0 = Clear and a score of 6 = Very Severe for the lesion severity. PGA Clear (0) is no plaque elevation over normal skin and no scale with or without erythema. Minimal (1) is possible plaque elevation but difficult to ascertain a slight elevation above normal skin. Percentage of participants: 0% to 100% (best).
| percentage of participants | Adalimumab + Placebo | Adalimumab + Calcipotriol/Betamethasone |
|---|---|---|
| Percentage of Participants Achieving a Physician's Global Assessment (PGA) of Clear or Minimal at Week 2 | 7.1 | 13.9 |
PGA is a physician's assessment of severity of disease (grading lesion severity). PGA scores range from 0 (best) to 6 (worst): on the 6-point scale, a score of 0 = Clear and a score of 6 = Very Severe for the lesion severity. PGA Clear (0) is no plaque elevation over normal skin and no scale with or without erythema. Minimal (1) is possible plaque elevation but difficult to ascertain a slight elevation above normal skin. Percentage of participants: 0% to 100% (best).
| percentage of participants | Adalimumab + Placebo | Adalimumab + Calcipotriol/Betamethasone |
|---|---|---|
| Percentage of Participants Achieving a Physician's Global Assessment (PGA) of Clear or Minimal at Week 4 | 24.5 | 33.1 |
PSSI is a physician assessment of clinical symptoms of scalp psoriasis. Computed as the sum of scores for erythema, induration, and desquamation (1 = absent; 4 = severest possible) multiplied by involved area (0 = 0%; 6 = 90-100%). Total score range: 0 (best) to 72 (worst). Negative change and percent change from Baseline indicate improvement.
| percent change in score | Adalimumab + Placebo | Adalimumab + Calcipotriol/Betamethasone |
|---|---|---|
| Percent Change in Psoriasis Scalp Severity Index (PSSI) From Baseline to Week 16. | -100.00 (-100.0 to -87.5) | -100.00 (-100.0 to -80.0) |
NAPSI is a sum of 2 scores that grade nail matrix psoriasis (based on presence/absence of pitting, leukonychia, red spots in the lunula, and nail plate crumbling) and nail bed psoriasis (based on presence/absence of onycholysis splinter hemorrhages, oil drop \[salmon patch\] discoloration, and nail bed hyperkeratosis). Each fingernail is given a single score based on presence of psoriasis in quadrant of nail: 0 (none) to 4 (present in 4/4 nail quadrants). Score range: 0 (best) to 80 (worst). Negative change and percent change from Baseline indicate improvement.
| percent change in score | Adalimumab + Placebo | Adalimumab + Calcipotriol/Betamethasone |
|---|---|---|
| Percent Change in Nail Psoriasis Severity Index (NAPSI) at Week 16. | -40.00 (-66.7 to 0.0) | -37.50 (-68.4 to 0.0) |
PGA is a physician's assessment of severity of disease (grading lesion severity). PGA scores range from 0 (best) to 6 (worst): on the 6-point scale, a score of 0 = Clear and a score of 6 = Very Severe for the lesion severity. PGA Clear (0) is no plaque elevation over normal skin and no scale with or without erythema. Minimal (1) is possible plaque elevation but difficult to ascertain a slight elevation above normal skin. Percentage of participants: 0% to 100% (best).
| percentage of participants | Adalimumab + Placebo | Adalimumab + Calcipotriol/Betamethasone |
|---|---|---|
| Percentage of Participants Achieving a Physician's Global Assessment (PGA) of Clear or Minimal at Week 8 | 46.2 | 42.9 |
PGA is a physician's assessment of severity of disease (grading lesion severity). PGA scores range from 0 (best) to 6 (worst): on the 6-point scale, a score of 0 = Clear and a score of 6 = Very Severe for the lesion severity. PGA Clear (0) is no plaque elevation over normal skin and no scale with or without erythema. Minimal (1) is possible plaque elevation but difficult to ascertain a slight elevation above normal skin. Percentage of participants: 0% to 100% (best).
| percentage of participants | Adalimumab + Placebo | Adalimumab + Calcipotriol/Betamethasone |
|---|---|---|
| Percentage of Participants Achieving a Physician's Global Assessment (PGA) of Clear or Minimal at Week 12 | 64.8 | 50.0 |
PGA is a physician's assessment of severity of disease (grading lesion severity). PGA scores range from 0 (best) to 6 (worst): on the 6-point scale, a score of 0 = Clear and a score of 6 = Very Severe for the lesion severity. PGA Clear (0) is no plaque elevation over normal skin and no scale with or without erythema. Minimal (1) is possible plaque elevation but difficult to ascertain a slight elevation above normal skin. Percentage of participants: 0% to 100% (best).
| percentage of participants | Adalimumab + Placebo | Adalimumab + Calcipotriol/Betamethasone |
|---|---|---|
| Percentage of Participants Achieving a Physicians Global Assessment (PGA) Response of Clear or Minimal at Week 16 | 64.6 | 56.6 |
DLQI is a participant-reported outcome consisting of a set of 10 questions regarding the degree to which (i.e., how much) the subject's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much, a lot, a little, or not at all. Total score range: 0 (best) to 30 (worst). Negative change and percent change from Baseline indicate improvement, with best improvement -100%.
| percent change in score | Adalimumab + Placebo | Adalimumab + Calcipotriol/Betamethasone |
|---|---|---|
| Percent Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 16 Compared With Baseline (Week 0) | -71.46 ± 49.171 | -67.20 ± 45.463 |
DLQI is a participant-reported outcome consisting of a set of 10 questions regarding the degree to which (i.e., how much) the subject's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much, a lot, a little, or not at all. Total score range: 0 (best) to 30 (worst). Negative change and percent change from Baseline indicate improvement, with best improvement -100%.
| percent change in score | Adalimumab + Placebo | Adalimumab + Calcipotriol/Betamethasone |
|---|---|---|
| Percent Change in the Dermatology Life Quality Index (DLQI) Total Score at Week 2 Compared With Baseline (Week 0) | -32.14 ± 44.118 | -47.49 ± 41.093 |
DLQI is a participant-reported outcome consisting of a set of 10 questions regarding the degree to which (i.e., how much) the subject's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much, a lot, a little, or not at all. Total score range: 0 (best) to 30 (worst). Negative change and percent change from Baseline indicate improvement, with best improvement -100%.
| percent change in score | Adalimumab + Placebo | Adalimumab + Calcipotriol/Betamethasone |
|---|---|---|
| Percent Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 4 Compared With Baseline (Week 0) | -46.64 ± 68.139 | -60.93 ± 38.122 |
DLQI is a participant-reported outcome consisting of a set of 10 questions regarding the degree to which (i.e., how much) the subject's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much, a lot, a little, or not at all. Total score range: 0 (best) to 30 (worst). Negative change and percent change from Baseline indicate improvement, with best improvement -100%.
| percent change in score | Adalimumab + Placebo | Adalimumab + Calcipotriol/Betamethasone |
|---|---|---|
| Percent Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 8 Compared With Baseline (Week 0) | -63.30 ± 45.404 | -62.30 ± 43.087 |
DLQI is a participant-reported outcome consisting of a set of 10 questions regarding the degree to which (i.e., how much) the subject's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much, a lot, a little, or not at all. Total score range: 0 (best) to 30 (worst). Negative change and percent change from Baseline indicate improvement, with best improvement -100%.
| percent change in score | Adalimumab + Placebo | Adalimumab + Calcipotriol/Betamethasone |
|---|---|---|
| Percent Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 12 Compared With Baseline (Week 0) | -69.49 ± 45.030 | -66.75 ± 49.195 |
Short Form 36 Health Survey (SF-36) Physical Component Score (PCS) is a participant-reported outcome that employs a questionnaire that asks for the participant's views about their health. Percent change at Week 16 is calculated as (Week 16 SF-36 PCS minus Week 0 SF-36 PCS) divided by Week 0 SF-36 PCS. Positive percent change in score indicates improvement, with best improvement 100%.
| percent change in score | Adalimumab + Placebo | Adalimumab + Calcipotriol/Betamethasone |
|---|---|---|
| Percent Change in Short Form 36 Health Survey (SF-36) Physical Component Score (PCS) at Week 16 Compared With Baseline (Week 0) | 20.53 ± 31.603 | 19.71 ± 32.136 |
Short Form 36 Health Survey (SF-36) Physical Component Score (PCS) is a participant-reported outcome that employs a questionnaire that asks for the participant's views about their health. Percent change at Week 8 is calculated as (Week 8 SF-36 PCS minus Week 0 SF-36 PCS) divided by Week 0 SF-36 PCS. Positive percent change in score indicates improvement, with best improvement 100%.
| percent change in score | Adalimumab + Placebo | Adalimumab + Calcipotriol/Betamethasone |
|---|---|---|
| Percent Change in Short Form 36 Health Survey (SF-36) Physical Component Score (PCS) at Week 8 Compared With Baseline (Week 0) | 19.35 ± 30.264 | 18.22 ± 29.967 |
Collected over Overall study. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Adalimumab + Placebo | — | 15/364 (4.1%) | 124/364 (34.1%) |
| Adalimumab + Calcipotriol/Betamethasone | — | 16/366 (4.4%) | 136/366 (37.2%) |
| Event | Adalimumab + Placebo | Adalimumab + Calcipotriol/Betamethasone |
|---|---|---|
| abortion infectedInfections and infestations | 1/113 | 0/116 |
| dermatitis exfoliativeSkin and subcutaneous tissue disorders | 2/364 | 0/366 |
| pneumoniaInfections and infestations | 0/364 | 2/366 |
| angina pectorisCardiac disorders | 1/364 | 0/366 |
| anaphylatic shockImmune system disorders | 1/364 | 0/366 |
| bronchopneumoniaInfections and infestations | 1/364 | 0/366 |
| erysipelasInfections and infestations | 1/364 | 1/366 |
| staphylococcal infectionInfections and infestations | 1/364 | 0/366 |
| musculoskeletal painMusculoskeletal and connective tissue disorders | 1/364 | 0/366 |
| lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/364 | 0/366 |
| Event | Adalimumab + Placebo | Adalimumab + Calcipotriol/Betamethasone |
|---|---|---|
| NasopharyngitisInfections and infestations | 23/364 | 32/366 |
| HeadacheNervous system disorders | 22/364 | 19/366 |
| PruritusSkin and subcutaneous tissue disorders | 21/364 | 13/366 |
| PsoriasisSkin and subcutaneous tissue disorders | 17/364 | 19/366 |
| CoughRespiratory, thoracic and mediastinal disorders | 12/364 | 11/366 |
| PharyngitisInfections and infestations | 12/364 | 7/366 |
| NauseaGastrointestinal disorders | 5/364 | 12/366 |
| DiarrhoeaGastrointestinal disorders | 7/364 | 11/366 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 7/364 | 11/366 |
| RhinitisInfections and infestations | 10/364 | 4/366 |
| Age, Categorical(Participants) | Adalimumab + Placebo | Adalimumab + Calcipotriol/Betamethasone | Total |
|---|---|---|---|
| <=18 years | 0 | 1 | 1 |
| Between 18 and 65 years | 343 | 350 | 693 |
| >=65 years | 21 | 15 | 36 |
| Age Continuous(years) | Adalimumab + Placebo | Adalimumab + Calcipotriol/Betamethasone | Total |
|---|---|---|---|
| Mean | 44.8 ± 12.61 | 45.3 ± 11.95 | 45.1 ± 12.28 |
| Sex: Female, Male(Participants) | Adalimumab + Placebo | Adalimumab + Calcipotriol/Betamethasone | Total |
|---|---|---|---|
| Female | 113 | 116 | 229 |
| Male | 251 | 250 | 501 |
| Region of Enrollment(participants) | Adalimumab + Placebo | Adalimumab + Calcipotriol/Betamethasone | Total |
|---|---|---|---|
| Austria | 12 | 12 | 24 |
| Belgium | 40 | 36 | 76 |
| Czech Republic | 8 | 10 | 18 |
| Denmark | 15 | 15 | 30 |
| Finland | 5 | 6 | 11 |
| France | 58 | 61 | 119 |
| Germany | 79 | 83 | 162 |
| Greece | 12 | 12 | 24 |
| Italy | 32 | 34 | 66 |
| Netherlands | 17 | 18 | 35 |
| Spain | 33 | 26 | 59 |
| Sweden | 9 | 8 | 17 |
| Switzerland | 12 | 10 | 22 |
| Turkey | 14 | 14 | 28 |
| United Kingdom | 18 | 21 | 39 |
Showing the first 100 of 131 sites across 15 countries. Choose a country and city above to see the rest.
The record gives a start of Nov 2007 and a primary completion of Oct 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2010, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Calcipotriene · Betamethasone